Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder a 6-month randomized controlled trial

JAMA

Volumn 283, Issue 23, 2000, Pages 3082-3088

  Gelenberg, Alan J ^a   Lydiard, R Bruce ^b   Rudolph, Richard L ^c   Aguiar, Loren ^c   Haskins, J Thomas ^c   Salinas, Eliseo ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VENLAFAXINE;

ADULT; ANXIETY NEUROSIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; TREATMENT OUTCOME; XEROSTOMIA;

EID: 0034697886     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.23.3082     Document Type: Article

References (23)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition. Washington, DC: American Psychiatric Association; 1987:251-252.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994:432, 435, 724-725.
3. Yonkers KA, Warshaw MG, Massion AO, Keller MB. Phenomenology and course of generalised anxiety disorder. Br J Psychiatry. 1996;168:308-313.
4. Barlow DH, Blanchard EB, Vermilyea JA, Vermilyea BB, DiNardo PA. Generalized anxiety and generalized anxiety disorder: description and reconceptualization. Am J Psychiatry. 1986;143:40-44.
5. Brown TA. The nature of generalized anxiety disorder and pathological worry: current evidence and conceptual models. Can J Psychiatry. 1997;42:817-825.
6. Brawman-Mintzer O, Lydiard RB. Generalized anxiety disorder: issues in epidemiology. J Clin Psychiatry. 1996;57(suppl 7):3-8.
7. Woodman CL, Breen K, Noyes R Jr, et al. The relationship between irritable bowel syndrome and psychiatric illness: a family study. Psychosomatics. 1998; 39:45-54.
8. Schweizer E. Generalized anxiety disorder: longitudinal course and pharmacologic treatment. Psychiatr Clin North Am. 1995;18:843-857.
9. Olfson M, Fireman B, Weissman MM, et al. Mental disorders and disability among patients in a primary care group practice Am I Psychiatry. 1997;154: 1734-1740.
10. Zajecka J. Importance of establishing the diagnosis of persistent anxiety. J Clin Psychiatry 1997; 58(suppl 3):9-13.
11. Flint AJ. Epidemiology and comorbidity of anxiety disorders in the elderly. Am J Psychiatry. 1994; 151:640-649.
12. Stoudemire A. Epidemiology and psychopharmacology of anxiety in medical patients. J Clin Psychiatry. 1996;57(suppl 7):64-72.
13. Massion AO, Warshaw MG, Keller MB. Quality of life and psychiatric morbidity in panic disorder and generalized anxiety disorder. Am J Psychiatry. 1993; 150:600-607.
14. Blazer DG, Hughes D, George LK, Schwartz M, Boyer R. Generalized anxiety disorder. In: Robins LN, Regier DA, eds. Psychiatric Disorders in America: The Epidemiologic Catchment Area Study. New York, NY: The Free Press; 1991:180-203.
15. Kessler RC, DuPont RL, Berglund P, Wittchen HU. Impairment in pure and comorbid generalized anxiety disorder and major depression at 12 months in two national surveys. Am J Psychiatry. 1999;156:1915-1923.
16. Kirkwood CK, Hayes PE. Anxiety disorders. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, eds. Pharmacotherapy. 3rd ed. Stamford, Conn: Appleton & Lange; 1997:1443-1462.
17. Rickels K, Downing R, Schweizer E, Hassman H. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry. 1993;50:884-895.
18. Feighner JP, Entsuah AR, McPherson MK. Efficacy of once-daily venlafaxine extended release (XR) for symptoms of anxiety in depressed outpatients. J Affect Disord. 1998;47:55-62.
19. Roy-Byrne P, Wingerson D, Cowley D, Dager S. Psychopharmacologic treatment of panic, generalized anxiety disorder, and social phobia. Psychiatr Clin North Am. 1993;16:719-735.
20. Rocca P, Fonzo V, Scotta M, Zanalda E, Ravizza L. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand. 1997;95:444-450.
21. Davidson JR, DuPont RL, Hedges D, Haskins JT. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry. 1999;60: 528-535.
22. Rickels K, Pollack M, Sheehan D, Haskins JT. Efficacy of venlafaxine extended-release (XR) capsules in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry. In press.
23. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID), I: history, rationale, and description. Arch Gen Psychiatry. 1992;49:624-629.